Synthesis and Evaluation of Antipsychotic Activity of 11-(4ᅢ까タᅡᄇ

Total Page:16

File Type:pdf, Size:1020Kb

Synthesis and Evaluation of Antipsychotic Activity of 11-(4ᅢ까タᅡᄇ Arabian Journal of Chemistry (2013) xxx, xxx–xxx King Saud University Arabian Journal of Chemistry www.ksu.edu.sa www.sciencedirect.com ORIGINAL ARTICLE Synthesis and evaluation of antipsychotic activity of 11-(40-(N-aryl carboxamido/N-aryl-a-phenyl-acetamido)- piperazinyl)-dibenz[b,f][1,4]-oxazepine derivatives Manoj S. Jain *, Sanjay J. Surana Department of Pharmaceutical Chemistry, R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur District, Dhule 425405, Maharashtra, India Received 14 January 2013; accepted 19 July 2013 KEYWORDS Abstract In the present study, a series of new substituted N-11-(40-N-aryl carboxamido/N-(aryl)- Dibenzoxazepine; a-phenyl-acetamido-piperazinyl)-dibenz[b,f][1,4]-oxazepine derivatives were designed on a revised Antipsychotic; structural model, length and nature of linker and introduced aryl group. All the compounds Carboxamido/acetamido; (MJ1–MJ12) were synthesized by economical route and confirmed by IR, 1H NMR, and mass spec- Catalepsy tral analyses. The antipsychotic potentialities of the synthesized derivatives were evaluated in mice by catalepsy and foot sock induced aggression. The present study demonstrates significant antipsy- chotic activity for most of the compounds from series. Compounds MJ-1, MJ-3 and MJ-4 were found to be potent antipsychotic compounds of the series at 5 mg/kg dose level when compared with the reference drug clozapine. ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. 1. Introduction observed that patients are liable to suffer from drug-induced extrapyramidal symptoms such as Parkinsonism, acute dys- Schizophrenia is one of the most widespread psychiatric disor- tonic reactions, akathisia, tardive dyskinesia and tardive dysto- ders and approximately 1.5–2% of the world’s population suf- nia (Chakrabarti et al., 1980; Work group on schizophrenia, fers from severe symptoms occupying more than half of the 1997). The introduction of the dibenzodiazepine antipsychotic beds in psychiatric clinics (The World Health Report, 2001). agent clozapine (8-chloro-11[4-methyl-1-piperazinyl]-5H- Currently many drugs are available for the treatment of psy- dibenzo-[b,e][1,4] diazepine) was an important development chosis. Ever since antipsychotics were introduced it has been in the pharmacotherapy of schizophrenia (Burki et al., 1975; Sayers et al., 1975). Preclinical and clinical investigations have shown that clozapine has properties different from those of * Corresponding author. Tel.: +91 9429459367; fax: +91 2563255189. classic neuroleptic agents, as well as a substantial therapeutic E-mail address: [email protected] (M.S. Jain). advantage (Kane et al., 1981; Lieberman et al., 1986; Peer review under responsibility of King Saud University. Lieberman et al., 1989). Clozapine was found to be one of the better choices for the treatment of refractory schizophrenia. Unlike classic neuroleptic agents, clozapine Production and hosting by Elsevier did not cause Parkinsonism, dystonia, or tardive dyskinesia, 1878-5352 ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. http://dx.doi.org/10.1016/j.arabjc.2013.07.033 Please cite this article in press as: Jain, M.S., Surana, S.J. Synthesis and evaluation of antipsychotic activity of 11-(40-(N-aryl carboxamido/N-aryl-a-phenyl- acetamido)-piperazinyl)-dibenz[b,f][1,4]-oxazepine derivatives. Arabian Journal of Chemistry (2013), http://dx.doi.org/10.1016/j.arabjc.2013.07.033 2 M.S. Jain, S.J. Surana nor did it elevate prolactin levels (Lieberman et al., 1989). De- chloride optics and are measured in cmÀ1. 1H NMR spectra spite the promise of clozapine, its use has been limited by its were recorded on Varian Mercury YH-300 MHZ (Gemini), propensity to cause agranulocytosis (Alvir et al., 1993). Bruker-500 MHz and Varian Unity-400 MHz spectrometer. The progress made in the area of QSAR and bioisosterism All experiments were carried out in CDCl3 as solvent and has opened an avenue to get better and safer drugs. Loxapine 1H chemical shift of the solvent was used as a secondary refer- and Clozapine belong to the class of dibenzoxazepine and dib- ence and referred to the TMS signal from the usual relation- enzodiazepine, respectively and they differ in pharmacody- ship; the values of the chemical shift (d) are given in ppm. namic profile (Wagh et al.,2007; Wagh et al., 2005). The Mass spectra were recorded on Jeol SX 102/Da-600 mass spec- Loxapine like drugs e.g. Clothiapine, Metiapine, and Zotepine; trometer, FAB gas at 10 kV accelerating voltage using a direct have an electronegative group at carbon-2 position that is rel- inlet system. FAB mass spectra were recorded at room temper- atively close to the side chain nitrogen and showed extrapyra- ature. Gas Chromatograms were recorded on Chemito-8610 midal side effects. On the other hand Clozapine like drugs e.g. HR using OV-101 column and B.P. 5 capillary column with Clozapine, Fluperlapine and Olanzapine all either lack a ring 0.5 l film thickness. substituent or have an electronegative group at C-8 position, much away from side chain nitrogen (Wagh et al., 2007). 3. Synthesis Therefore, Clozapine has thus inspired a search for additional, safer, ‘atypical’ agents with antipsychotic activity and low risk 3.1. Synthesis of 2-nitro-20-methyl diphenyl ether carboxylate of extrapyramidal side effects. Pharmacological investigation (3) of series of clozapine analogues revealed that optimal length of the hydrocarbon linker between N40 and the introduced aryl A mixture of o-Fluoro nitrobenzene (10 gm, 0.070 mol), anhy- system (phenyl) was two to four atoms (Capuano et al., 2003). drous potassium carbonate (14.7 g, 0.1066 mol) and methyl Both Clozapine and Loxapine on N-demethylation (at N4 of salicylate (16.2 g, 0.1066 mol) was transferred in a 500 ml piperazine) produce less active or toxic metabolite (Capuano round bottomed flask, equipped with a sealed mechanical stir- et al., 2003). Consequently, keeping the view of blocking the rer and a reflux condenser and contents were refluxed in diox- N-demethylation metabolism of Clozapine and Loxapine in ane for 10 h. The reaction was monitored by GC. The reaction our mind we have blocked N4 demethylation by substituting mixture was dumped in water, extracted with toluene, the ex- alkyl or aryl acetamido group at N4 of piperazine so as to in- tract washed with 5% solution of sodium hydroxide. Toluene crease half-life of drug and reduce side effects. Keeping this was then distilled off to give thick liquid of 2-nitro-20-methyl view in mind and continuation of our research toward devel- diphenyl ether carboxylate. Yield = 18 g (93%). opment of potent antipsychotic agents (Wagh et al., 2007), herein, we have incorporated an N-aryl carboxamido/N- 3.2. Synthesis of 2-amino-20-methyl diphenyl ether carboxylate (aryl)-a-phenyl-acetamido-piperazinyl substituted at N4 of (4) piperazine in dibenzoxazepine derivatives to improve their antipsychotic potential. Several synthetic routes were reported 0 for the synthesis of tricyclic ring, Stutton et al. reported syn- To a 2-nitro-2 -methyl-diphenyl ether carboxylate (3) (18 g, thesis using 2-chloro nitro benzene and phenol in the presence 0.066 mol) was added 100 ml of methanol followed by the of copper followed by reduction, phosgenation and cyclization addition of 1 g of Raney nickel, in a stainless steel hydrogena- (Stutton, 1969). In other route, 2-amino diphenyl ether was re- tion bottle and the reaction mixture was hydrogenated at acted with ethyl chloroformate followed by phosphorous oxy- 70 psi pressure, the reaction monitored by TLC. The catalyst chloride (Smits et al., 2006). We have tried for a new route of was filter and methanol was distilled-off under reduced pres- 0 synthesis using 2-fluoro nitrobenzene and methyl salicylate in sure to get the desired product, almost pure 2-amino-2 -meth- presence of potassium carbonate followed by reduction with yldiphenyl ether carboxylate, Yield = 13.5 g (82%). raney nickel and cyclization at 150 °C. In present work we have not only developed new route of synthesis using commer- 3.3. Synthesis of 11-Oxadibenz[b,f][1,4] oxazepine (5) cially available raw material but also achieve good yield with better antipsychotic potency of the target derivatives. In a 100 ml round bottomed flask, 2-amino-20-methyldiphenyl ether carboxylate (4) (10 g, 0.041 mol), 50 ml dimethyl form- 2. Methods and materials amide, and 0.5 ml sulfuric acid were added and refluxed for 15 h, the reaction was monitored by TLC. After the comple- All solvents and chemicals used in the synthesis were procured tion of reaction, it was cooled to room temperature and from commercial suppliers and purified whenever necessary. dumped in 200 ml water. Off-white colored precipitate was fil- Progress of the reaction was monitored by TLC using Chloro- tered and dried. m.p. 210–212 °C. Yield = 6.8 g (79%). form:acetone (9:1) system. The o-fluoro nitrobenzene, methyl salicylate, dioxane, potassium carbonate, methanol, pipera- 3.4. 11-chloro-dibenz[b,f][1,4] oxazepine (6) zine, xylene, phosphorus oxychloride and a-chloro phenylace- tic acid were procured from Rankem labs. Raney Ni and In a 500 ml round bottomed flask, 11-oxo-dibenzo [b,f][1,4] oxa- triphosgene were procured from sampro organic research zepine (5) (5 g, 0.023 mol), 50 ml POCl3 and 1 g N,N-dimethyl lab. Melting points (mp) were determined using Veego micro- aniline were mixed and refluxed for 18 h. The excess POCl3 processor based programmable melting point apparatus, in was distilled out under vacuum and the residue was extracted open capillaries and were uncorrected. Infrared spectra were with toluene (2 · 50 ml).
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe Et Al
    US 2011 01 05536A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe et al. (43) Pub. Date: May 5, 2011 (54) DOSING REGIMENASSOCATED WITH Publication Classification LONG-ACTING INUECTABLE PALIPERDONE ESTERS (51) Int. Cl. A 6LX 3/59 (2006.01) (76) Inventors: Peter H. Lewyn-Briscoe, A6IP 25/18 (2006.01) Newtown, PA (US); Cristiana Gassmann-Mayer, Pennington, NJ (US); Srihari Gopal, Belle Meade, (52) U.S. Cl. ................................................... S14/259.41 NJ (US); David W. Hough, Wallingford, PA (US); Bart M.M. Remmerie, Gent (BE); Mahesh N. (57) ABSTRACT Samtani, Flemington, NJ (US) The present application provides a method for treating (21) Appl. No.: 12/916,910 patients in need of psychiatric treatment, wherein said patient (22) Filed: Nov. 1, 2010 misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides Related U.S. Application Data a method for treating psychiatric patients in need of a Switch (60) Provisional application No. 61/256,696, filed on Oct. ing treatment to paliperidone palmitate in a Sustained release 30, 2009. formulation. Patent Application Publication May 5, 2011 Sheet 1 of 6 US 2011/O105536 A1 FIG. 1 First-Order PrOCeSS Cp V CL Central (2) Zero-Order PrOCeSS Patent Application Publication May 5, 2011 Sheet 2 of 6 US 2011/O105536 A1 FIG. 2 25mgeq 50mgeq m-100mde::::: Missed doSe On WK 4. Patient returns On WK5 Missed doSe On WK 4. Patient returns On WK 6 -8-4 O 4 8 12 16 2024 -8-4 O 4 8 12 1620 24 Missed doSe On WK 4.
    [Show full text]
  • Known Active Compounds Used in This Article
    Known active compounds used in this article As COX-2 active compounds, 12 inhibitors and 2 natural ligands were selected. The two natural ligands were arachidonic acid and prostaglandin H2. The 12 inhibitors were diclofenac, etodolac, suprofen, diflunisal, piroxicam, sulindac, indomethacin, ketoprofen, naproxen, nimesulide, rofecoxib, and 1-phenylsulfonamide-3-trifluoromethyl-5-parabromophenylpyrazole. The names of the thermolysin inhibitors used in the present study are as follows, with the PDB code in parentheses representing the complex structure from which the compound originated: l-benzylsuccinate (1hyt), phenylalanine phosphinic acid - deamino-methyl-phenylalanine (1os0), (6-methyl-3,4-dihydro-2H-chromen-2-Yl) methylphosphonate (1pe5), 2-(4-methylphenoxy) ethylphosphonate - 3-methylbutan-1-amine (1pe7), 2-ethoxyethylphosphonate - 3-methylbutan-1-amine (1pe8), (2-sulfanyl-3-phenylpropanoyl)-Phe-Tyr (1qf0), [2(R,S)-2-sulfanylheptanoyl]-Phe-Ala (1qf1), [(2S)-2-sulfanyl-3-phenylpropanoyl]-Gly-(5-phenylproline) (1qf2), n-(1-(2(R, S)-carboxy-4-phenylbutyl) cyclopentylcarbonyl)- (S)-tryptophan (1thl), (R)-retrothiorphan (1z9g), (S)-thiorphan (1zdp), hydroxamic acid (4tln), phenylalanine phosphinic acid (4tmn), Honh-benzylmalonyl-L-alanylglycine-P-nitroanilide (5tln), 1 Cbz-GlyP-Leu-Leu (ZgPLl) (5tmn), Cbz-GlyP-(O)-Leu-Leu (ZgP(O)Ll) (6tmn), CH2CO(N-OH)Leu-OCH3 (7tln), benzyloxycarbonyl-D-Ala (1kto), benzyloxycarbonyl-L-Ala (1kl6), benzyloxycarbonyl-D-Thr (1kro), benzyloxycarbonyl-L-Thr (1kj0), benzyloxycarbonyl-D-Asp (1ks7), benzyloxycarbonyl-L-Asp
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,138,169 B2 Oronsky Et Al
    USOO8138169B2 (12) United States Patent (10) Patent No.: US 8,138,169 B2 Oronsky et al. (45) Date of Patent: Mar. 20, 2012 (54) COMBINATION THERAPY FOR BIPOLAR 6,863,901 B2 3/2005 Hirsh et al. 7,201.920 B2 4/2007 Kumar et al. DSORDER 2007/0213394 A1 9/2007 Beguin et al. (75) Inventors: Bryan T. Oronsky, Los Altos Hills, CA FOREIGN PATENT DOCUMENTS (US); Neil C. Oronsky, Los Altos Hills, WO WO-200806691.6 A1 6, 2008 CA (US) OTHER PUBLICATIONS (73) Assignee: ComgenRx, Inc., Mountain View, CA Boothby et al. Buprenorphine for the treatment of opioid depen (US) dence. American Journal of Health-System Pharamcy, 2007, 64 (3), pp. 266-272, abstract.* (*) Notice: Subject to any disclaimer, the term of this Brown, et al., “Naltrexone in Patients with Bipolar Disorder and patent is extended or adjusted under 35 Alcohol Dependence.” Depression and Anxiety, 2006, vol. 23, No. 8, pp. 492-495. U.S.C. 154(b) by 424 days. Carlezon, et al., “Kappa-Opioid Ligands in the Study and Treatment of Mood Disorders.” Pharmacology and Therapeutics, (21) Appl. No.: 12/422,156 XP002548302, Sep. 2009, vol. 123, No. 3, pp. 334-343. International Search Report and Written Opinion mailed on Jan. 25. (22) Filed: Apr. 10, 2009 2010, for PCT Application No. PCT/US2009/040272, 17 pages. Kamin, et al., “Extrapyramidal Side Effects in the Psychiatric Emer (65) Prior Publication Data gency Service.” Psychiatric Service, Mar. 2000, vol. 51, No. 3, pp. US 2009/0311347 A1 Dec. 17, 2009 287-289. Levin, et al., "Bipolar Disorder and Substance abuse.” Biological Psychiatry, XP004649079, vol.
    [Show full text]
  • 1 PUBLICATIONS Barry Blackwell ARTICLES
    Profiles (Publications) December 4, 2014 PUBLICATIONS Barry Blackwell ARTICLES: 1. Blackwell, B.: Why Patients Come to a Casualty Department. Lancet. (1962), 1:369. 2. Blackwell, B.: Acute Leukemia Presenting as a Lump in the Breast. British Journal of Surgery. (1963), 225:769-771. 3. Lehmann, H., Liddell, J., Blackwell, B., O’Connor, D.C., Daws, A.V.: Two Further Serum Pseudocholinesterase Phenotypes as Causes of Suxamethonium Apnoea. British Medical Journal. (1963), 1:1116-1118. 4. Blackwell, B.: Hypertensive Crisis Due to MAOI. Lancet. (1963), 2:849-851. 5. Blackwell, B.: Munchausen at Guy’s. Guy’s Hospital Reports. (1963), 114 (3):257-277. 6. Blackwell, B.: The Management of Barbituate Overdose in Nonspecialized Units. British Journal of Clinical Practice. (1964), 18 (3):135-144. 7. Blackwell, B., Mallett, B.L.: Psychiatric Illness in a Casualty Department. Guy’s Hospital Reports. (1964), 113:123-130. 8. Blackwell, B., Marley, E.: Interaction Between Cheese and MAOI in Rats and Cats. Lancet. (1964), 1:530-531. 9. Blackwell, B., Davis, B.: Psychiatric Aspects of Myclonus Epilepsy. British Journal of Clinical Practice. (1964), 18 (9):513-516. 10. Palmai, G., Blackwell, B.: The Diurnal Pattern of Salivary Flow in Normal and Depressed Patients. British Journal of Psychiatry. (1965), 111:334-338. 11. Blackwell, B., Mabbitt, L.A.: Tyramine in Cheese Related to Hypertensive Crisis after MAOI. Lancet. (1965), 1:938-940. 12. Blackwell, B., Marley, E., Mabbitt, L.A.: Effects of Yeast Extract after MAOI. Lancet. (1965), 1:940-943. 13. Blackwell, B.: The Simplified Management of Barbituate Overdose. International Medical Digest. (1966), 1:41.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Fluphenazine Decanoate (Timing of Administration) for People with Schizophrenia (Protocol)
    Cochrane Database of Systematic Reviews Fluphenazine decanoate (timing of administration) for people with schizophrenia (Protocol) Abbas F, Rajab T, Alsamarrai O, Alhalabi N, Zaher Addeen S, Mheish O, Aljojo A, Essali A Abbas F, Rajab T, Alsamarrai O, Alhalabi N, Zaher Addeen S, Mheish O, Aljojo A, Essali A. Fluphenazine decanoate (timing of administration) for people with schizophrenia. Cochrane Database of Systematic Reviews 2017, Issue 10. Art. No.: CD012810. DOI: 10.1002/14651858.CD012810. www.cochranelibrary.com Fluphenazine decanoate (timing of administration) for people with schizophrenia (Protocol) Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 BACKGROUND .................................... 1 Figure1. ..................................... 3 OBJECTIVES ..................................... 4 METHODS ...................................... 4 ACKNOWLEDGEMENTS . 11 REFERENCES ..................................... 11 CONTRIBUTIONSOFAUTHORS . 14 DECLARATIONSOFINTEREST . 14 SOURCESOFSUPPORT . 15 Fluphenazine decanoate (timing of administration) for people with schizophrenia (Protocol) i Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Protocol] Fluphenazine decanoate (timing of administration) for people with schizophrenia Fatima Abbas1, Tawfik Rajab1, Omar Alsamarrai1, Nawras Alhalabi2, Sarah Zaher Addeen1, Oubadah Mheish1, Aisha Aljojo3,
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    THE ORGANIC CHEMISTRY OF DRUG SYNTHESIS VOLUME 3 DANIEL LEDNICER Analytical Bio-Chemistry Laboratories, Inc. Columbia, Missouri LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS New York • Chlchester • Brisbane * Toronto • Singapore Copyright © 1984 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging In Publication Data: (Revised for volume 3) Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." Includes bibliographical references and index. 1. Chemistry, Pharmaceutical. 2. Drugs. 3. Chemistry, Organic—Synthesis. I. Mitscher, Lester A., joint author. II. Title. [DNLM 1. Chemistry, Organic. 2. Chemistry, Pharmaceutical. 3. Drugs—Chemical synthesis. QV 744 L473o 1977] RS403.L38 615M9 76-28387 ISBN 0-471-09250-9 (v. 3) Printed in the United States of America 10 907654321 With great pleasure we dedicate this book, too, to our wives, Beryle and Betty. The great tragedy of Science is the slaying of a beautiful hypothesis by an ugly fact. Thomas H. Huxley, "Biogenesis and Abiogenisis" Preface Ihe first volume in this series represented the launching of a trial balloon on the part of the authors. In the first place, wo were not entirely convinced that contemporary medicinal (hemistry could in fact be organized coherently on the basis of organic chemistry.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,197,764 B1 Bradley Et Al
    USOO6197764B1 (12) United States Patent (10) Patent No.: US 6,197,764 B1 Bradley et al. (45) Date of Patent: *Mar. 6, 2001 (54) CLOZAPINE COMPOSITIONS AND USES FOREIGN PATENT DOCUMENTS THEREOF 0599 576A1 1/1994 (EP). (75) Inventors: Matthews O. Bradley, Laytonsville, 693498 1/1996 (EP). MD (US); Victor E. Shashoua, 61204136 11/1984 (JP). Belmont, MA (US); Charles S. 06-072868 3/1994 (JP). Swindell, Merion; Nigel L. Webb, 6072868 3/1994 (JP). Bryn Mawr, both of PA (US) 7082146 3/1996 (JP). 8151334 6/1996 (JP). (73) Assignee: Protarga, Inc., Conshohocken, PA (US) 9030963 2/1997 (JP). (*) Notice: Subject to any disclaimer, the term of this WO 89/07938 9/1989 (WO). patent is extended or adjusted under 35 WO 96/04001 2/1996 (WO). U.S.C. 154(b) by 0 days. WO 96/22303 7/1996 (WO). WO 96/27380 9/1996 (WO). This patent is Subject to a terminal dis WO98/17325 4/1998 (WO). claimer. OTHER PUBLICATIONS (21) Appl. No.: 08/978,541 (22) Filed: Nov. 26, 1997 Bourat, et al., "Long Chain Esters of Pipotiazine as Lon g-Acting Psychotropic Pro-Drug, Med. Chem. Proc. Int. (51) Int. Cl. .............................................. A61K 31/00 Symp. 5th (1976) pp. 105-114. (52) U.S. Cl. ........................... 514/218; 514/219; 514/220 Lohr, et al., “Neuroleptic-Induced Movement Disorders . (58) Field of Search ..................................... 514/218, 219, ..", Psychiatry, vol. 3, (1989). 514/220 Makino, et al., Chemical Abstracts, vol. 106, No. 12, (56) References Cited (90.177x) issued Mar. 23, 1987, “Pharmaceuticals Permeable to Blood-Brain Barrier'.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]